An Open Label, Parallel Group, Multicenter Study, Evaluating the Safety and Imaging Characteristics of Florbetapir (18F) in Healthy Volunteers, Patients With Mild Cognitive Impairment (MCI) and Patients With Alzheimer's Disease (AD)
Latest Information Update: 06 Nov 2021
At a glance
- Drugs Florbetapir F 18 (Primary)
- Indications Alzheimer's disease; Mild cognitive impairment
- Focus Diagnostic use
- Sponsors Avid Radiopharmaceuticals
Most Recent Events
- 17 Oct 2014 New trial record